StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultJul 29, 2026, 04:24 PM

Repligen Q2 Net Income $5.0M, Revenue $204.1M; Divests Polymem

AI Summary

Repligen reported a mixed second quarter for 2026, with total revenue increasing to $204.1 million from $182.4 million year-over-year. However, net income significantly decreased to $5.0 million from $14.9 million in the prior year's quarter, resulting in diluted EPS of $0.09, down from $0.26. The company completed the divestiture of Polymem S.A.S. for $3.6 million, incurring a net loss of $13.7 million, and continued its restructuring activities with charges of $4.2 million for the first six months of the year.

Key Highlights

  • Q2 2026 net income was $5.0 million, down from $14.9 million in Q2 2025.
  • Q2 2026 total revenue increased to $204.1 million from $182.4 million in Q2 2025.
  • Diluted EPS for Q2 2026 was $0.09, compared to $0.26 in Q2 2025.
  • Divested Polymem S.A.S. on March 30, 2026, for $3.6 million.
  • Recognized a net loss of $13.7 million on the sale of Polymem S.A.S.
  • Cash and cash equivalents totaled $606.8 million as of June 30, 2026.
  • Restructuring charges for the six months ended June 30, 2026, were $4.2 million.
  • Cash provided by operating activities was $61.1 million for the six months.